Literature DB >> 15085166

Technique for intrapartum administration of surfactant without requirement for an endotracheal tube.

John Kattwinkel1, Melinda Robinson, Barry T Bloom, Paula Delmore, James E Ferguson.   

Abstract

OBJECTIVE: To evaluate the feasibility and safety of administering surfactant into the nasopharynx during delivery, thus permitting the baby to aspirate the solution into the fluid-filled airway as an air-fluid interface is established. This process avoids the endotracheal intubation (ETI) and positive pressure ventilation (PPV) usually associated with prophylaxis, thus avoiding the pulmonary barotrauma associated with the conventional method of surfactant administration. STUDY
DESIGN: In all, 23 neonates weighing 560 to 1804 g and born at 27 to 30 weeks had their nasopharyngeal airways suctioned and then 3.0-4.5 ml Infasurf instilled into the nasopharynx before delivery of the shoulders. Continuous positive airway pressure (CPAP) of 10 cmH(2)O was administered by mask as the babies initiated breathing. Nasal CPAP at 6 cmH(2)O was then continued for a minimum of 48 hours.
RESULTS: In all, 13 of 15 babies delivered vaginally were weaned quickly to room air and required no further surfactant or endotracheal intubation for RDS. Five of eight babies delivered by C-section required subsequent endotracheal intubation soon after birth and two received subsequent endotracheal tube surfactant.
CONCLUSION: Nasopharyngeal surfactant instillation at birth appears to be relatively safe and simple to accomplish, especially for vaginal births. A large randomized clinical trial will be required to determine the efficacy of this technique when compared to prophylaxis by endotracheal intubation and to nCPAP alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085166     DOI: 10.1038/sj.jp.7211103

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  21 in total

1.  Effect of Surfactant Therapy Using Orogastric Tube for Tracheal Catheterization in Preterm Newborns with Respiratory Distress.

Authors:  Rampal Singh Tomar; Ranjit Ghuliani; Dinesh Yadav
Journal:  Indian J Pediatr       Date:  2017-01-03       Impact factor: 1.967

Review 2.  Surfactant therapy: the current practice and the future trends.

Authors:  Khalid Altirkawi
Journal:  Sudan J Paediatr       Date:  2013

Review 3.  Global report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions.

Authors:  Fernando C Barros; Zulfiqar Ahmed Bhutta; Maneesh Batra; Thomas N Hansen; Cesar G Victora; Craig E Rubens
Journal:  BMC Pregnancy Childbirth       Date:  2010-02-23       Impact factor: 3.007

Review 4.  Intra-amniotic surfactant for women at risk of preterm birth for preventing respiratory distress in newborns.

Authors:  Mohamed E Abdel-Latif; David A Osborn; Daniel Challis
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 5.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08

6.  Early administration of surfactant via a thin intratracheal catheter in preterm infants with respiratory distress syndrome: Feasibility and outcome.

Authors:  Majid Mohammadizadeh; Azam Ghehsareh Ardestani; Ali Reza Sadeghnia
Journal:  J Res Pharm Pract       Date:  2015 Jan-Mar

Review 7.  Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future?

Authors:  Emmanuel Lopez; Géraldine Gascoin; Cyril Flamant; Mona Merhi; Pierre Tourneux; Olivier Baud
Journal:  BMC Pediatr       Date:  2013-10-10       Impact factor: 2.125

8.  The role of surfactant in respiratory distress syndrome.

Authors:  Christopher Cheng-Hwa Ma; Sze Ma
Journal:  Open Respir Med J       Date:  2012-07-13

9.  Novel approaches to surfactant administration.

Authors:  Samir Gupta; Steven M Donn
Journal:  Crit Care Res Pract       Date:  2012-12-03

Review 10.  The Implications of Metabotypes for Rationalizing Therapeutics in Infants and Children.

Authors:  Theodora Katsila; George P Patrinos
Journal:  Front Pediatr       Date:  2015-07-29       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.